AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02617043 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated whole breast irradiation with simultaneously integrated boost
Description: deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: tACS treatment week
Description: 10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS treatment week
Description: 10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS sham week
Description: 10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: tACS sham week
Description: 10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Maintenance tACS
Description: 10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maintenance tACS
Description: 10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Maintenance Sham tACS
Description: 10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
Study NCT03221270 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Maintenance Sham tACS
Description: 10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
Study NCT02256657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Toolkit
Description: The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
Study NCT01984983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
Study NCT02180087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketoprofen
Study NCT01984983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline placebo
Study NCT02180087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoprofen
Study NCT04653714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
Study NCT04653714 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling and root planing
Description: Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
Study NCT04653714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lozenges
Description: Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
Study NCT04653714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges
Description: Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
Study NCT02966158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIT Group
Description: The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period.
Study NCT01334957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Description: 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
Study NCT03285464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triplanar Rotary Resistance
Description: Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
Study NCT03285464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triplanar Rotary Resistance
Description: Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
Study NCT03880149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Each omega-3 capsule contains 600 mg, including 400 mg EPA + 200 mg Docosahexaenoic acid (DHA) and 400 IU of vitamin E for 5 omega-3 capsules. Omega-3 dosage: 1 g per 15 kg body mass
Study NCT03880149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medium-chain triglyceride (MCT) and vitamin E
Study NCT05807230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-level network rehabilitation services within the medical alliance
Description: Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
Study NCT02173808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: levonorgestrel butanoate
Study NCT01354457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab and 90Y-Epratuzumab
Description: Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
Study NCT00955318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6500
Description: Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
Study NCT01893203 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BF-200 ALA cream
Description: The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
Study NCT01893203 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MAL cream
Description: The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
Study NCT02323243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allium  Bulbar Urethral Stent  (BUS) system
Study NCT03808129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Lidocaine
Description: ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine iontophoresis
Description: Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis
Description: Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprussiate iontophoresis
Description: Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprussiate iontophoresis
Description: Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ppi water iontophoresis
Description: ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ppi water iontophoresis
Description: ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
Study NCT01250327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare stent
Description: insertion of a bare metal stent
Study NCT01250327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: conventional surgery methode
Study NCT00684684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chartis System
Description: Assessment of airway flow and pressure
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler recording
Description: Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
Study NCT02652065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Doppler recording
Description: Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
Study NCT01443208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine
Description: one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
Study NCT01443208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine
Description: one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
Study NCT01443208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine
Description: two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
Study NCT02486523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygiene promotion sessions
Description: Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
Study NCT02486523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Household WASH package
Description: The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
Study NCT02486523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household visit
Description: A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
Study NCT02486523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group discussions after successful discharge
Description: Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
Study NCT02486523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group discussions after successful discharge
Description: Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
Study NCT02486523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Therapeutic Programme
Description: Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
Study NCT02486523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient Therapeutic Programme
Description: Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
Study NCT03012009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: full ablative CO2 laser
Description: ablation to the level of de dermal papilla
Study NCT03012009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional ablative CO2 laser
Description: 180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
Study NCT03012009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL
Study NCT03012009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED lamp
Description: peak wavelength 630 nm, 37J/cm2
Study NCT03012009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride 2% with epinephrine
Study NCT04905966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education and Physical activity intervention
Description: Schools randomized to the experimental group received nutrition education sessions and physical activity classes.
Study NCT04783818 — intervention group
Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: PMRT
Study NCT02925117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablet for oral use
Study NCT02925117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet for oral use
Study NCT02925117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT02925117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study NCT02885207 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Focal epilepsy of unknown cause
Description: Male or female 18-65 years presenting focal epilepsy on the following arguments:~* Crisis with clinical symptoms indicating focal seizure~* \& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~* No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~* No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~* No argument for metabolic or neurodegenerative genetic epilepsy.~* Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines).
Study NCT02663908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT02663908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Study NCT01593085 — intervention group
Intervention type: BEHAVIORAL
Intervention: interview with a doctor for evaluating suicide risk
Description: patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~--------------------------------------------------------------------------------
Study NCT02487433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib MR 22 mg (Fed)
Description: A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
Study NCT02487433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib MR 22 mg (Fasted)
Description: A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
Study NCT01932359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rapidly absorbable suture (Vicryl Rapide)
Study NCT01932359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-absorbable suture (Ethilon)
Study NCT03598543 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention, this is an obervational study.
Study NCT01269411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT01269411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT01269411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01269411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative
Study NCT04727073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Spironolactone
Description: Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was > 30 mL/min/m2 and potassium \< 4.5 mmol/L.
Study NCT04727073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
Study NCT02259101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I Treatment Condition
Description: Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
Study NCT02259101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SH Comparison Condition
Description: Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
Study NCT02819739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical oxygen
Study NCT02819739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical oxygen
Study NCT03798197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg estetrol (E4)
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
Study NCT03798197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg estetrol (E4)
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).